双平台战略提速：仙乐健康谋“A+H”上市，打造全球营养健康赛道新引擎

Core Viewpoint - Xianle Health, a leading company in China's nutrition and health food industry, has submitted its main board listing application to the Hong Kong Stock Exchange, marking a significant step towards establishing an "A+H" dual capital platform. This move coincides with the company's forecast of a substantial decline in net profit for 2025, raising market concerns about its future prospects [1][4]. Group 1: Financial Performance and Strategic Adjustments - The anticipated short-term decline in net profit is attributed not to weak core business performance but rather to strategic adjustments and early investments in new sectors [4]. - The company has recognized an asset impairment loss of 195 million yuan related to its personal care business, preparing for its divestiture, which, while impacting current profits, will allow for a stronger focus on core nutrition health solutions in the long run [4]. - Xianle Health's revenue for 2024 is projected to reach 4.211 billion yuan, with its core product forms, soft capsules and gummies, holding the second-largest global market share. The compound annual growth rates for revenue from 2022 to 2024 are expected to be 41% and 30%, respectively, indicating strong organic growth potential [4]. Group 2: Strategic Intent and Market Positioning - The decision to pursue a Hong Kong listing during a period of profit pressure reflects a clear strategic intent to leverage the international capital market for financing and global influence, thereby accelerating its globalization efforts [5]. - The global nutrition and health food market is experiencing rapid expansion, particularly in segments like soft capsules and gummies. Establishing an "A+H" dual platform will not only optimize the company's capital structure but also enhance its international brand reputation, providing robust support for overseas market expansion, supply chain optimization, and potential acquisitions [5]. - Long-term, the strategic transformation is expected to open new growth avenues for the company. Divesting non-core businesses will allow for a more focused approach in consolidating its leading position in nutrition health solutions, while continued investment in promising sectors like precision nutrition and pet nutrition is aimed at nurturing future growth [7].